Related Experiment Video
Updated: Aug 14, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Uncommon metastases in renal carcinoma]
Carlos Arroyo1, Pedro Palacios, Norma Uribe
1Departamento de Urología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D. F., México. jck1@yahoo.com
Introduction:
Renal clear cell carcinoma (RCCCa) represents 2-3% of the neoplasms in the adult population, and can be metastastatic in up to 30% at the time of diagnosis. In these cases its mortality can be of up to 99% in 5 years, due to the lack of response to current treatments, unless it is a single, surgically resectable metastasis. Currently, there is no explanation for its routes of progression, it even seems to be non existent based on the rare tumor implant sites.
Objective:
To report unusual metastasis from RCCCa and a review of the literature.
Material And Methods:
We reviewed retrospectively 15 years of patient records diagnosed with metastasic CaRCC different from: local lymph nodes, lung, bone or liver. We identified 11 cases: brain (2), duodenum (2), tonsils, thyroid, esophagus, diaphragm, testicle, adrenal gland and soft tissue of the knee.
Conclusion:
A description of this and other literature series with rare metastasis was done, as well as an analysis of possible routes and mechanisms responsible for the unusual tumor progression in RCCCa. We need to continue investigating the dissemination pathways and other cellular conditions involved in metastastatic kidney cancer in order to better understand and improve the treatment of patients in advanced stages.
More Related Videos
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management

